BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Palbociclib: trial readouts and FDA decisions
4 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Pfizer, Merck Sharp & Dohme LLC, Stemline Therapeutics, Inc., Celcuity Inc, AstraZeneca. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-22 est. | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT05468697 A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LI | Renal Cell Carcinoma | active not recruiting | 60 |
| 2026-12-27 est. | P1/P2 | Stemline Therapeutics, Inc. | NCT05563220 Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | Breast Cancer; Metastatic Breast Cancer | active not recruiting | 435 |
| 2026-12-30 est. | P3 | Pfizer PFE | NCT05909397 Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | Breast Cancer | active not recruiting | 59 |
| 2026-12-31 est. | P2 | Pfizer PFE | NCT04553133 PF-07104091 as a Single Agent and in Combination Therapy | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | active not recruiting | 157 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-06-30 est. | P3 | Celcuity Inc CELC | NCT05501886 Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer ( | Breast Cancer | active not recruiting | 701 |
| 2026-06-26 | P3 | AstraZeneca AZN | NCT04711252 A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Receiv | ER-Positive HER2-Negative Breast Cancer | active not recruiting | 1371 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.